Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib hydrochloride and celecoxib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Celecoxib may also stop the growth of
lung cancer by blocking blood flow to the tumor. Giving erlotinib hydrochloride together with
celecoxib may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well giving erlotinib hydrochloride
together with celecoxib works compared with erlotinib hydrochloride alone in treating
patients with stage IIIB-IV non-small cell lung cancer.